Shanghai, China

Shuhui Chen

USPTO Granted Patents = 195 

 

Average Co-Inventor Count = 6.2

ph-index = 5

Forward Citations = 159(Granted Patents)

Forward Citations (Not Self Cited) = 131(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:

goldMedal52 out of 65 
 
Medshine Discovery Inc.
 patents
silverMedal20 out of 118 
 
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 patents
bronzeMedal9 out of 13 
 
Guangdong Raynovent Biotech Co., Ltd.
 patents
47 out of 8 
 
Zhuhai United Laboratories Co., Ltd.
 patents
56 out of 15 
 
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
 patents
65 out of 31 
 
Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.
 patents
75 out of 8 
 
Cstone Pharmaceuticals
 patents
85 out of 5 
 
Wuxi Biocity Biopharmaceutics Co., Ltd.
 patents
94 out of 5 
 
Guangdong Zhongsheng Pharmaceutical Co., Ltd
 patents
104 out of 10 
 
Shandong Danhong Pharmaceutical Co., Ltd.
 patents
114 out of 7 
 
Cstone Pharmaceuticals (shanghai) Co., Ltd.
 patents
124 out of 5 
 
Shijiazhuang Sagacity New Drug Development Company, Ltd.
 patents
134 out of 6 
 
Cisen Pharmaceutical Co., Ltd.
 patents
143 out of 11 
 
Qilu Pharmaceutical Co., Ltd.
 patents
153 out of 4 
 
Harbin Zhenbao Pharmaceutical Co., Ltd.
 patents
163 out of 5 
 
Luoxin Pharmaceutical (shanghai) Co., Ltd.
 patents
173 out of 3 
 
D3 Bio (wuxi) Co., Ltd.
 patents
183 out of 5 
 
Hubei Bio-pharmaceutical Industrial Technological Institute Inc.
 patents
193 out of 4 
 
Humanwell Healthcare (group) Co., Ltd.
 patents
203 out of 5 
 
Cgenetech (suzhou, China) Co., Ltd.
 patents
213 out of 3 
 
Guangzhou Joyo Pharmatech Co., Ltd.
 patents
223 out of 4 
 
Wuxi Fortune Pharmaceutical Co., Ltd
 patents
233 out of 3 
 
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
 patents
242 out of 5 
 
Cstone Pharmaceuticals (suzhou) Co., Ltd.
 patents
252 out of 3 
 
Fujian Cosunter Pharmaceutical Co., Ltd.
 patents
262 out of 5 
 
Genfleet Therapeutics (shanghai) Inc.
 patents
272 out of 2 
 
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory
 patents
282 out of 2 
 
Wuxi Life Fountain Biotech Co., Ltd
 patents
292 out of 13 
 
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
 patents
302 out of 6 
 
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
 patents
312 out of 2 
 
Helioeast Science & Technology Co., Ltd.
 patents
322 out of 2 
 
Jumbo Drug Bank Co., Ltd.
 patents
332 out of 2 
 
China Resources Pharmaceutical Holdings Company Limited
 patents
342 out of 2 
 
Cstone Pharmaceutical (suzhou) Co., Ltd.
 patents
352 out of 2 
 
Changzhou Yinsheng Pharmaceutical Co., Ltd.
 patents
362 out of 235 
 
Sichuan University
 patents
371 out of 20 
 
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
 patents
381 out of 26 
 
Yangtze River Pharmaceutical Group Co., Ltd.
 patents
391 out of 1 
 
North China Pharmaceutical Company., Ltd.
 patent
401 out of 4 
 
Zhongshan Ophthalmic Center, Sun Yat-sen University
 patents
411 out of 2 
 
Phaeno Therapeutics Co., Ltd.
 patents
421 out of 1 
 
Fuijan Cosunter Pharmaceutical Co. Ltd.
 patent
431 out of 2 
 
Heilongjiang Zhenbaodao Pharmaceutical Co, Ltd
 patents
441 out of 1 
 
Shenzhen Salubris Pharm Co Ltd.
 patent
451 out of 11 
 
Nanjing Sanhome Pharmaceutical Co., Ltd.
 patents
461 out of 2 
 
Shenzhen Optimum Biological Technology Co., Ltd
 patents
471 out of 1 
 
Zhuohe Pharmaceutical Group Co., Ltd
 patent
481 out of 1 
 
China Resources Biopharmaceutical Company Limited
 patent
491 out of 7 
 
Fujian Akeylink Biotechnology Co., Ltd.
 patents
501 out of 1 
 
Novaonco Js Therapeutics Co., Ltd.
 patent
511 out of 1 
 
Hangzhou Sciwind Biosciences Co., Ltd
 patent
521 out of 1 
 
Helioeast Pharmaceutical Co., Ltd.
 patent
531 out of 5 
 
Kpc Pharmaceuticals, Inc.
 patents
541 out of 1 
 
Cspc Zhongqi Pharmaceuticall Technology (shijiazhuang) Co., Ltd.
 patent
551 out of 1 
 
Guangdong Xianqiang Pharmaceutical Co., Ltd
 patent
561 out of 3 
 
Simcere Pharmaceutical Co., Ltd.
 patents
571 out of 1 
 
Shliazhuang Sagacity New Drug Development Co., Ltd.
 patent
581 out of 1 
 
Chongqing Pharmaceutical Industrial Research Institute Co. Ltd.
 patent
591 out of 5 
 
Yaopharma Co., Ltd.
 patents
601 out of 3 
 
Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
 patents
611 out of 20 
 
Shandong Luye Pharmaceutical Co., Ltd.
 patents
621 out of 1 
 
Guizhou Inochini Technology Co., Ltd
 patent
631 out of 1 
 
North China Pharmaceutical New Drug R&d Co., Ltd.
 patent
641 out of 16 
 
Jiangsu Kanion Pharmaceutical Co., Ltd.
 patents
651 out of 1 
 
Zhejiang Longcharm Bio-tech Pharma. Co., Ltd.
 patent
661 out of 1 
 
Dongbao Purple Star (hangzhou) Biopharmaceutical Co., Ltd.
 patent
671 out of 4 
 
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
 patents
681 out of 1 
 
Nicoya Therapeutics (shanghai) Co., Ltd
 patent
691 out of 1 
 
Guangzhou Consun Pharmaceutical Co. Ltd
 patent
706 out of 832,718 
Other
 patents
where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Jak Inhibitor
Atr Inhibitor
Retinal Diseases
Multi-Targeted Inhibitor
Kras G12C Inhibitor
SGLT2/DPP4 Inhibitor
Fgfr Inhibitor
Vegfr Inhibitor
Btk Inhibitor
Tgf-Βr1 Kinase Inhibitor
Pd-L1 Immunomodulator
Her2 Inhibitor
195 patents (USPTO):Explore Patents

Title: Shuhui Chen: Innovative Solutions and Patents in Shanghai

Introduction:

Shuhui Chen, a prolific inventor based in Shanghai, China, has made significant contributions to the field of pharmaceuticals and related industries. With an impressive number of 136 patents to his name, Chen has consistently demonstrated his expertise and innovative thinking. This article sheds light on his latest patents, his career highlights, and his valuable collaborations with notable colleagues.

Latest Patents:

Chen's most recent patents highlight his contributions to the development of novel compounds with potential therapeutic applications. One of his noteworthy patents is titled "Benzo 2-azaspiro[4.4]nonane compound and use thereof." This patent discloses a series of benzo 2-azaspiro[4.4]nonane compounds, with a specific emphasis on a compound represented by formula (P) and its pharmaceutically acceptable salt. This breakthrough has the potential to pave the way for new treatments in the medical industry.

Another remarkable patent is titled "Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound." This patent introduces a crystal form (formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound, along with its preparation method. The crystal form's application in the manufacturing of medicines for treating related diseases showcases Chen's ability to harness materials for therapeutic purposes effectively.

Career Highlights:

Chen's impressive 136 patents reflect his extensive experience and expertise. Throughout his career, he has worked with leading companies in the pharmaceutical sector, including Medshine Discovery Inc. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. These collaborations have provided Chen with invaluable opportunities to apply and further develop his inventive ideas within a professional setting.

Collaborations:

One of Chen's notable collaborators is Jian Li, a distinguished individual who has contributed significantly to the pharmaceutical industry. The partnership between Chen and Li has likely fueled groundbreaking discoveries and advancements. Additionally, Charles Z Ding, another colleague, has contributed to Chen's journey as a valuable collaborator. Together, they may have pushed the boundaries of innovation and invention in pharmaceuticals.

Conclusion:

Shuhui Chen's remarkable record of 136 patents underscores his immense capability as an inventive mind in the field of pharmaceuticals. His latest patents, such as the benzo 2-azaspiro[4.4]nonane compound and the crystal form of 2-methyl-2-propanol and amino-substituted aryl compound, demonstrate his commitment to finding novel solutions with potential therapeutic applications.

Chen's collaborations with prominent individuals like Jian Li and Charles Z Ding have likely played a pivotal role in harnessing collective expertise and pushing forward innovative ideas. As Chen continues his journey, it will be fascinating to see what groundbreaking contributions he will make next, further advancing the realm of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…